D-NAME (hydrochloride)
(Synonyms: NG-硝基-D-精氨酸甲基酯盐酸盐) 目录号 : GC19437
A less active enantiomer of the NO synthase inhibitor L-NAME
Cas No.:50912-92-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
N(G)-Nitro-D-arginine methyl ester (D-NAME) is the less active enantiomer of the nitric oxide (NO) synthase inhibitor N(G)-nitro-L-arginine methyl ester . D-NAME was initially thought to be inactive and was often used as a negative control for L-NAME. Later studies showed that D-NAME (40 mg/kg/day in rats) can have similar but less pronounced effects as L-NAME (40 mg/kg/day in rats) in the cardiovascular system, particularly at long-term timepoints. D-NAME (3-10 µg/mouse) had no effect on nociception in mice assessed using the tail flick test.
References:
[1].Palmer, R.M.J., Rees, D.D., Ashton, D.S., et al. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation Biochem. Biophys. Res. Commun. 153(3), 1251-1256 (1988).
[2]. Chinellato, A., Froldi, G., Caparrota, L., et al. Pharmacological characterization of endothelial cell nitric oxide synthase inhibitors in isolated rabbit aorta Life Sci. 62(6), 479-490 (1998).
[3].Babál, P., Pechánová, O., and Bernátová, I. Long-term administration of D-NAME induces hemodynamic and structural changes in the cardiovascular system Physiol. Res. 49(1), 47-54 (2000).
[4].Kawabata, A., Umeda, N., and Takagaki, H. L-arginine exerts a dual role in nociceptive processing in the brain: Involvement of the kyotorphin-Met-enkephalin pathway and NO-cyclic GMP pathway Br. J. Pharmacol. 109(1), 73-79 (1993).
| Cas No. | 50912-92-0 | SDF | |
| 别名 | NG-硝基-D-精氨酸甲基酯盐酸盐 | ||
| Canonical SMILES | [H]N(/C(N([H])CCC[C@@H](N)C(OC)=O)=N/[H])[N+]([O-])=O.Cl | ||
| 分子式 | C7H15N5O4 • HCl | 分子量 | 269.7 |
| 溶解度 | DMF: 20 mg/ml,DMSO: 20 mg/ml,PBS (pH 7.2): 10 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.7078 mL | 18.5391 mL | 37.0782 mL |
| 5 mM | 0.7416 mL | 3.7078 mL | 7.4156 mL |
| 10 mM | 0.3708 mL | 1.8539 mL | 3.7078 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet